March 5, 2021 -- The U.S. Patent and Trademark Office (USPTO) has awarded Humanigen two patents for the use of lenzilumab.
The first patent is for the use of lenzilumab to reduce nongranulocyte-macrophage colony-stimulating factor (GM-CSF) cytokines/chemokines that contribute to immunotherapy-related toxicity. The second patent covers lenzilumab's use in improving the efficacy and durability of immunotherapy.
Lenzilumab binds to and neutralizes GM-CSF -- a key initiator of the inflammatory cascade triggering immunotherapy-related toxicities, including cytokine storm and neurotoxicity. These conditions have prolonged hospitalization and intensive care unit stays.
Neutralizing the activity of GM-CSF signaling reduces downstream pro-inflammatory mediators and nullifies cytokine response syndrome while also improving T-cell function, Humanigen said.